Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBT (2016 - 2025)

Coherus Oncology's EBT history spans 13 years, with the latest figure at -$46.3 million for Q4 2025.

  • For Q4 2025, EBT fell 0.55% year-over-year to -$46.3 million; the TTM value through Dec 2025 reached -$183.1 million, down 1.89%, while the annual FY2025 figure was -$183.1 million, 14.98% up from the prior year.
  • EBT for Q4 2025 was -$46.3 million at Coherus Oncology, down from -$44.5 million in the prior quarter.
  • Across five years, EBT topped out at -$10.8 million in Q3 2024 and bottomed at -$172.9 million in Q1 2021.
  • The 5-year median for EBT is -$46.9 million (2025), against an average of -$59.0 million.
  • The largest annual shift saw EBT plummeted 573.76% in 2021 before it soared 73.14% in 2024.
  • A 5-year view of EBT shows it stood at -$45.7 million in 2021, then dropped by 28.87% to -$58.9 million in 2022, then tumbled by 35.3% to -$79.7 million in 2023, then skyrocketed by 42.13% to -$46.1 million in 2024, then decreased by 0.55% to -$46.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EBT are -$46.3 million (Q4 2025), -$44.5 million (Q3 2025), and -$44.9 million (Q2 2025).